Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)

Conditions

• Kidney Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - 120 Years

Healthy Volunteers

Not accepted

Interventions

• bevacizumab — BIOLOGICAL
  10mg/kg IV infusion on Days 1 \& 15 of each cycle
• recombinant interferon alfa — BIOLOGICAL
  9 million units subQ injection 3 x/week for 4 weeks

Study Details

RATIONALE: Biological therapies, such as interferon alfa-2b, may interfere with the growth of tumor cells. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known whether interferon alfa-2b is more effective with or without bevacizumab in treating advanced renal cell carcinoma (kidney cancer). PURPOSE: This randomized phase III trial is studying interferon alfa-2b and bevacizumab to see how well they work compared to interferon alfa-2b alone in treating patients with advanced renal cell carcinoma.

Key Dates

First listed

Nov 6, 2003

Start date

Oct 31, 2003

Status verified

Jul 2016

Primary completion

Jan 31, 2004

Completion

Nov 30, 2012

Study Design

Enrollment

732 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Interferon
  Treatment with interferon alfa 2b
• Experimental: Interferon + bevacizumab
  Addition of bevacizumab to interferon alfa 2b treatment

Primary Outcome Measure

Overall Survival [ Time Frame: 5 years ]

Locations (489)

Find similar trials in Birmingham, AL

Related Studies

• Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland